Search Results - "Leutgeb, B."

IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications by Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S.N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., Zanghi, J.A., Leutgeb, B., Felip, E.

“…Atezolizumab intravenous (IV) is approved for the treatment of various solid tumours. To improve treatment convenience and health care efficiencies, a…”
Get full text

O10.04 THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE by Herrlinger, U., Schafer, N., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Leutgeb, B., Urbach, H., Stummer, W., Glas, M.

“…BACKGROUND: There is a need for more effective therapies in newly diagnosed glioblastoma (GBM) patients with an MGMT-non-methylated tumor. The GLARIUS trial…”
Get full text

477P Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) by Lenz, H.J., Weberpals, J., Cremolini, C., Grothey, A., Leutgeb, B., Mahrus, S., Nimeiri, H., Reyes-Rivera, I., Seligmann, J., Tabernero, J., Tejpar, S., Yoshino, T., Stintzing, S.

Get full text

61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) by Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez Baranda, L.A., Liu, S., Chan, P., Shearer-Kang, E., Shivhare, M., Tosti, N., Zanghi, J., Leutgeb, B., Felip, E.

Get full text

Enhancement of a constitutively active promoter for gene therapy by a positive feed-back transcriptional activator mechanism by Veelken, H, Leutgeb, B, Kulmburg, P, Fiebig, H H, Mackensen, A, Lindemann, A

“…Success of gene replacement therapy depends on long-term, high level expression of the transgene. Gene therapy vectors incorporating a promoter of a…”
Get more information

O10.04THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE by Herrlinger, U., Schäfer, N., Steinbach, J.P., Weyerbrock, A., Hau, P., Goldbrunner, R., Leutgeb, B., Urbach, H., Stummer, W., Glas, M.

“…BACKGROUND: There is a need for more effective therapies in newly diagnosed glioblastoma (GBM) patients with an MGMT-non-methylated tumor. The GLARIUS trial…”
Get full text

Overall Survival According to Patient Subgroups: Results from a Pooled Analysis of 5 Observational or Phase Iv Studies of Bevacizumab in Metastatic Colorectal Cancer by Grothey, A., Arnold, D., Van Cutsem, E., Bekaii-Saab, T., Kozloff, M., Bennouna, J., Revil, C., Donica, M., Sommer, N., Leutgeb, B., Ekstrand-Olsen, M., Hermann, F., Hurwitz, H.

Get full text

520POVERALL SURVIVAL ACCORDING TO PATIENT SUBGROUPS: RESULTS FROM A POOLED ANALYSIS OF 5 OBSERVATIONAL OR PHASE IV STUDIES OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER by Grothey, A., Arnold, D., Van Cutsem, E., Bekaii-Saab, T., Kozloff, M., Bennouna, J., Revil, C., Donica, M., Sommer, N., Leutgeb, B., Ekstrand-Olsen, M., Hermann, F., Hurwitz, H.

“…Abstract Aim: Randomized controlled trials (RCTs) have demonstrated benefits in overall survival (OS) for patients (pts) with metastatic colorectal cancer…”
Get full text